Endo Health Solutions 8K Bank of America Merrill Lynch 2011 Healthcare Conference | ENDP 11 May 11

ENDO PHARMACEUTICALS

Bank of America Merrill Lynch 2011 Healthcare Conference

May 12, 2011

Exhibit 99.1

grow. collaborate. innovate. thrive.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. Statements including words such as “believes,”

“expects,”

“anticipates,”

“intends,”

“estimates,”

“plan,”

“will,”

“may,”

“look forward,”

“intend,”

“guidance,”

“future”

or similar

expressions are forward-looking statements. Because these statements reflect our current views,

expectations and beliefs concerning future events, these forward-looking statements involve risks and

uncertainties. Investors should note that many factors, as more fully described under the caption “Risk

Factors”

in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission

and as otherwise enumerated herein or therein, could affect our future financial results and could cause

our actual results to differ materially from those expressed in forward-looking statements contained in

our Annual Report on Form 10-K. The forward-looking statements in this presentation are qualified by

these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to

differ materially from expected and historical results. We assume no obligation to publicly update any

forward-looking statements, whether as a result of new information, future developments or otherwise.

grow. collaborate. innovate. thrive.

STRONG OPERATING PERFORMANCE

16% 3-YEAR CAGR FOR REVENUE*

* Revenue CAGR 2007-2010.

Revenue

Cash Flow from Operations

grow. collaborate. innovate. thrive.

Through Organic Growth

•

Diversified business lines to maximize growth

•

Enhanced commercial model driving growth

via strategic resource deployment

•

Invested in R&D portfolio yielding a diversified

pipeline of products and a recent FDA

approval

•

Bolstered management team by adding

expertise and experience in managing and

growing a larger enterprise

ENDO’S TRANSFORMATION

Through Strategic Growth

•

With Indevus, we secured a position in urology

•

HealthTronics gave us an established presence

in Devices & Services and critical mass in

urology

•

Penwest strengthened our pain business

enhancing profitability & flexibility in the opioid

franchise

•

Qualitest brings critical mass to our generics

business & strengthens our pain portfolio

•

AMS establishes scale in devices

and services and solidifies our position covering

the urology market –

Now expected to close in

2Q 2011

grow. collaborate. innovate. thrive.

30%

25%

28%

17%

DIVERSIFIED HEALTHCARE SOLUTIONS COMPANY

37%

32%

10%

21%

46%

33%

21%

Lidoderm®

Generic

Men’s

Health

12/31/10: $2.14B

(1)

12/31/10: $0.54B

(2)

12/31/10: $2.68B

(3)

Revenue mix

Endo

AMS

Pro Forma

Pro forma for full year of 2010 acquisitions of Qualitest, HealthTronics and Penwest

Excludes $4.2MM of discontinued operations

Includes full year of AMS acquisition

Other Branded

Devices &

Services

Women’s

Health

BPH

Lidoderm®

Generic

Other Branded

Devices &

Services

Revenue mix

27%

73%

International

grow. collaborate. innovate. thrive.

ENDO’S INTEGRATED BUSINESS MODEL

grow. collaborate. innovate. thrive.

STRONG CORE BUSINESS SUPPORTING GROWTH

grow. collaborate. innovate. thrive.

NEW TESTOSTERONE REPLACEMENT THERAPY

14 million men suffer with hypogonadism in US

9% are treated

Market TRx Net Sales: >$1.2B

Growth Rate: approximately 20% CAGR last 5 years

Gels have the greatest utilization in the TRT market: ~72%

PCPs account for majority of TRT prescriptions:

More than 60% through Primary Care Physicians

Approximately 30% through specialty (Urologists/Endocrinologists)

Method of Payment for TRT class:

Approximately 80% Commercial

Approximately 12% Government

Remainder from Cash Payment

grow. collaborate. innovate. thrive.

2011 ENDO GUIDANCE

Guidance

Revenue range

$2.35B -

$2.45B

Adjusted diluted EPS range

$4.20 -

$4.30

Reported (GAAP) diluted EPS range

$2.25 -

$2.35

ENDO PHARMACEUTICALS

grow. collaborate. innovate. thrive.

RECONCILIATION OF NON-GAAP MEASURES

For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s Current Report on Form 8-K filed today with the Securities and Exchange Commission

Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for the Year Ending December 31, 2011

Lower End of Range

Upper End of Range

Projected GAAP diluted income per common share

$2.25

$2.35

Upfront and milestone-related payments to partners

$0.35

Amortization of commercial intangible assets and inventory step-up

$1.35

Acquisition and integration costs related to recent acquisitions.

$0.35

Interest expense adjustment for ASC 470-20 and the amortization of

the premium on debt acquired from Indevus

$0.16

Tax effect of pre-tax adjustments at the applicable tax rates and

certain other expected cash tax savings as a result of recent

acquisitions

($0.26)

Diluted adjusted income per common share guidance

$4.20

$4.30

The company's guidance is being issued based on certain assumptions including:

•Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results

•Includes all completed business development transactions as of April 28, 2011

•Includes certain expenses associated with the acquisition of American Medical Systems, Inc.

ENDO PHARMACEUTICALS

Bank of America Merrill Lynch 2011 Healthcare Conference

May 12, 2011

Endo Health Solutions (ENDP) Inactive 8-KBank of America Merrill Lynch 2011 Healthcare Conference